Cargando…

Combined Treatment of an Intratumoral Injection of Dendritic Cells and Systemic Chemotherapy (Paclitaxel) for Murine Fibrosarcoma

A novel combined treatment of conventional chemotherapy with an intratumoral injection of syngeneic dendritic cells (DCs) has emerged as a potent cancer treatment strategy. In this study, we evaluated the synergistic effect of an intraperitoneal (i.p.) injection of a chemotherapeutic drug, paclitaxe...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Gwang-Seong, Lee, Moon-Hee, Kim, Soon-Ki, Kim, Chul-Soo, Lee, Hong-Sik, Im, Moon-Whan, Kil, Hye-Yun, Seong, Do-Hwan, Lee, Jong-Rok, Kim, Woo-Chul, Lee, Min-Geol, Song, Sun U.
Formato: Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810599/
https://www.ncbi.nlm.nih.gov/pubmed/16385661
http://dx.doi.org/10.3349/ymj.2005.46.6.835
_version_ 1782176700154511360
author Choi, Gwang-Seong
Lee, Moon-Hee
Kim, Soon-Ki
Kim, Chul-Soo
Lee, Hong-Sik
Im, Moon-Whan
Kil, Hye-Yun
Seong, Do-Hwan
Lee, Jong-Rok
Kim, Woo-Chul
Lee, Min-Geol
Song, Sun U.
author_facet Choi, Gwang-Seong
Lee, Moon-Hee
Kim, Soon-Ki
Kim, Chul-Soo
Lee, Hong-Sik
Im, Moon-Whan
Kil, Hye-Yun
Seong, Do-Hwan
Lee, Jong-Rok
Kim, Woo-Chul
Lee, Min-Geol
Song, Sun U.
author_sort Choi, Gwang-Seong
collection PubMed
description A novel combined treatment of conventional chemotherapy with an intratumoral injection of syngeneic dendritic cells (DCs) has emerged as a potent cancer treatment strategy. In this study, we evaluated the synergistic effect of an intraperitoneal (i.p.) injection of a chemotherapeutic drug, paclitaxel, and an intratumoral (i.t.) injection of syngeneic bone marrow-derived DCs for the treatment of pre-existing fibrosarcoma. Subcutaneous tumors were established using MCA102 fibrosarcoma cells in syngeneic C57BL/6 mice. The results demonstrated that the combined treatment of paclitaxel chemotherapy and the injection of DCs led to complete tumor regression, in contrast to only partial eradication of the tumors with chemotherapy or DCs alone. Furthermore, the tumor-free mice were able to resist a repeat challenge with the same type of tumor. These findings suggest that a combination therapy of systemic chemotherapy along with the intratumoral administration of DCs is a potent treatment strategy for fibrosarcoma.
format Text
id pubmed-2810599
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-28105992010-01-26 Combined Treatment of an Intratumoral Injection of Dendritic Cells and Systemic Chemotherapy (Paclitaxel) for Murine Fibrosarcoma Choi, Gwang-Seong Lee, Moon-Hee Kim, Soon-Ki Kim, Chul-Soo Lee, Hong-Sik Im, Moon-Whan Kil, Hye-Yun Seong, Do-Hwan Lee, Jong-Rok Kim, Woo-Chul Lee, Min-Geol Song, Sun U. Yonsei Med J Original Article A novel combined treatment of conventional chemotherapy with an intratumoral injection of syngeneic dendritic cells (DCs) has emerged as a potent cancer treatment strategy. In this study, we evaluated the synergistic effect of an intraperitoneal (i.p.) injection of a chemotherapeutic drug, paclitaxel, and an intratumoral (i.t.) injection of syngeneic bone marrow-derived DCs for the treatment of pre-existing fibrosarcoma. Subcutaneous tumors were established using MCA102 fibrosarcoma cells in syngeneic C57BL/6 mice. The results demonstrated that the combined treatment of paclitaxel chemotherapy and the injection of DCs led to complete tumor regression, in contrast to only partial eradication of the tumors with chemotherapy or DCs alone. Furthermore, the tumor-free mice were able to resist a repeat challenge with the same type of tumor. These findings suggest that a combination therapy of systemic chemotherapy along with the intratumoral administration of DCs is a potent treatment strategy for fibrosarcoma. Yonsei University College of Medicine 2005-12-31 2005-12-31 /pmc/articles/PMC2810599/ /pubmed/16385661 http://dx.doi.org/10.3349/ymj.2005.46.6.835 Text en Copyright © 2005 The Yonsei University College of Medicine http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Choi, Gwang-Seong
Lee, Moon-Hee
Kim, Soon-Ki
Kim, Chul-Soo
Lee, Hong-Sik
Im, Moon-Whan
Kil, Hye-Yun
Seong, Do-Hwan
Lee, Jong-Rok
Kim, Woo-Chul
Lee, Min-Geol
Song, Sun U.
Combined Treatment of an Intratumoral Injection of Dendritic Cells and Systemic Chemotherapy (Paclitaxel) for Murine Fibrosarcoma
title Combined Treatment of an Intratumoral Injection of Dendritic Cells and Systemic Chemotherapy (Paclitaxel) for Murine Fibrosarcoma
title_full Combined Treatment of an Intratumoral Injection of Dendritic Cells and Systemic Chemotherapy (Paclitaxel) for Murine Fibrosarcoma
title_fullStr Combined Treatment of an Intratumoral Injection of Dendritic Cells and Systemic Chemotherapy (Paclitaxel) for Murine Fibrosarcoma
title_full_unstemmed Combined Treatment of an Intratumoral Injection of Dendritic Cells and Systemic Chemotherapy (Paclitaxel) for Murine Fibrosarcoma
title_short Combined Treatment of an Intratumoral Injection of Dendritic Cells and Systemic Chemotherapy (Paclitaxel) for Murine Fibrosarcoma
title_sort combined treatment of an intratumoral injection of dendritic cells and systemic chemotherapy (paclitaxel) for murine fibrosarcoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810599/
https://www.ncbi.nlm.nih.gov/pubmed/16385661
http://dx.doi.org/10.3349/ymj.2005.46.6.835
work_keys_str_mv AT choigwangseong combinedtreatmentofanintratumoralinjectionofdendriticcellsandsystemicchemotherapypaclitaxelformurinefibrosarcoma
AT leemoonhee combinedtreatmentofanintratumoralinjectionofdendriticcellsandsystemicchemotherapypaclitaxelformurinefibrosarcoma
AT kimsoonki combinedtreatmentofanintratumoralinjectionofdendriticcellsandsystemicchemotherapypaclitaxelformurinefibrosarcoma
AT kimchulsoo combinedtreatmentofanintratumoralinjectionofdendriticcellsandsystemicchemotherapypaclitaxelformurinefibrosarcoma
AT leehongsik combinedtreatmentofanintratumoralinjectionofdendriticcellsandsystemicchemotherapypaclitaxelformurinefibrosarcoma
AT immoonwhan combinedtreatmentofanintratumoralinjectionofdendriticcellsandsystemicchemotherapypaclitaxelformurinefibrosarcoma
AT kilhyeyun combinedtreatmentofanintratumoralinjectionofdendriticcellsandsystemicchemotherapypaclitaxelformurinefibrosarcoma
AT seongdohwan combinedtreatmentofanintratumoralinjectionofdendriticcellsandsystemicchemotherapypaclitaxelformurinefibrosarcoma
AT leejongrok combinedtreatmentofanintratumoralinjectionofdendriticcellsandsystemicchemotherapypaclitaxelformurinefibrosarcoma
AT kimwoochul combinedtreatmentofanintratumoralinjectionofdendriticcellsandsystemicchemotherapypaclitaxelformurinefibrosarcoma
AT leemingeol combinedtreatmentofanintratumoralinjectionofdendriticcellsandsystemicchemotherapypaclitaxelformurinefibrosarcoma
AT songsunu combinedtreatmentofanintratumoralinjectionofdendriticcellsandsystemicchemotherapypaclitaxelformurinefibrosarcoma